Nexalin Technology shares surge 22.71% premarket after expanding peer-reviewed research validates DIFS technology.

Nexalin Technology (NXL) surged 22.71% in premarket trading following the announcement that it highlighted its expanding body of peer-reviewed neuroimaging research, validating its DIFS™ technology as a leader in evidence-based non-invasive brain stimulation. The recent GlobeNewswire update emphasized the growing scientific credibility of Nexalin’s platform, including studies demonstrating cognitive improvements in Alzheimer’s and ADHD, as well as regulatory progress in Alzheimer’s disease programs. These developments, particularly the reinforcement of clinical and technological leadership, align with the stock’s sharp premarket rally, reflecting investor optimism about the company’s therapeutic pipeline and market potential.